KLK-7 / Kallikrein-7 / PRSS6 Antibody (Antigen Affinity Purified)

Kallikrein-7 / PRSS6 / KLK7 Antibody ( Antigen Affinity Purified )

Kallikrein-7 / PRSS6 / KLK7 Antibody Product Information

• Immunogen: Recombinant human KLK7 protein ( Catalog#10416-H08H )
• Antibody Type: Rabbit Polyclonal Antibody ( Antibody Purification Platform )
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: Produced in rabbits immunized with purified, human cell-derived, recombinant human KLK7 ( rh KLK7 ; Catalog#10416-H08H ; NP_005037.1 ; Met 1 - Arg 253 ). KLK7 specific IgG was purified by human KLK7 affinity chromatography

Kallikrein-7 / PRSS6 / KLK7 Antibody Usage Guide

• Specificity: Human Kallikrein-7 / KLK7
• Western blot: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human KLK7 in WB. Using a DAB detection system, the detection limit for human KLK7 is approximately 0.5 ng/lane under non-reducing conditions and 1 ng/lane under reducing conditions
• Direct ELISA: This antibody can be used at 0.1 - 0.2 μg/mL with the appropriate secondary reagents to detect human KLK7. The detection limit for human KLK7 is approximately 0.00245 ng/well
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Kallikrein-7 / PRSS6 / KLK7 Antibody Background

Kallikrein-7, also known as kallikrein-related peptidase 7, Stratum corneum chymotryptic enzyme, Serine protease 6, KLK7, and PRSS6, is a secreted protein which belongs to the peptidase S1 family and Kallikrein subfamily. Members of the Kallikrein family are involved in various malignancies such as prostate ( PSA, KLK2, KLK15 ), ovarian ( KLK4, KLK5, KLK6, KLK8, KLK10 ), and breast cancer ( KLK10, KLK13, KLK14 ). Kallikrein-7 / KLK7 appears to be increased in ovarian cancer and higher KLK7 expression in ovarian cancer tissue is associated with poorer prognosis of ovarian cancer patients. Kallikrein-7 / KLK7 is abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Kallikrein-7 / KLK7 is up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at the protein level). It was significantly associated with shorter overall survival (OS) and disease-free survival (DFS). Kallikrein-7 / KLK7 may catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. KLK7 also plays a role in the activation of precursors to inflammatory cytokines

References

1. Dong,Y. et al., 2003, Clin Cancer Res. 9 (5):1710-20.
2. Kyriakopoulou, LG. et al., 2003, Clin Biochem. 36 (2):135-43.
3. Talieri, M. et al.,2004,Thromb Haemost. 91 (1):180-6.
4. Talieri, M. et al., 2009, Thromb Haemost. 101 (4): 741-7.